Search company, investor...

Predict your next investment

Venture Capital
illuminaventures.com

Investments

62

Portfolio Exits

5

Funds

2

Partners & Customers

1

Service Providers

1

About Illumina Ventures

Illumina Ventures pursues investments in early stage companies that are pioneering new applications of nucleic acid sequencing, developing products that will expand the genomics ecosystem, and utilizing genomics to improve human health.

Headquarters Location

499 Illinois Street Suite 210

San Francisco, California, 94158,

United States

858-210-1824

Want to inform investors similar to Illumina Ventures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Illumina Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Illumina Ventures in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Research containing Illumina Ventures

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Illumina Ventures in 1 CB Insights research brief, most recently on Jan 31, 2022.

Latest Illumina Ventures News

Illumina Ventures Announces New Partner, Mara Aspinall, Has Joined Its Investment Team

Sep 23, 2023

Posted on San Francisco, CA — September 21, 2023 — Illumina Ventures today announced that Mara Aspinall, MBA, has joined the Company’s investment team as a Partner. Mara G. Aspinall “Mara brings more than 30 years of leadership experience in genomics and the diagnostics industry to this position,” said Nick Naclerio, PhD, Illumina Ventures Founding Partner. “Her experience ranges from early-stage start-ups to established public companies, and she is recognized as a thought leader in the diagnostics field.”  Most recently, Mara served as co-founder and managing director of BlueStone Venture Partners. Previously, she was president and CEO of Ventana Medical Systems, a billion-dollar division of The Roche Group (now Roche Tissue Diagnostics), where she oversaw a world-class team that achieved more than two dozen major instrument and assay launches, as well as global leadership in companion diagnostics. During her tenure at the Genzyme Corporation, Mara served as President of both Genzyme Genetics and Pharmaceuticals, transforming the former from a small, specialized player to one of the top five clinical laboratories in the US and the latter to an international leader in specialized pharmaceutical ingredient manufacturing. Mara has served on the boards of numerous public and private companies. Mara was named Arizona Biosciences Leader of the Year by the Arizona Biotechnology Association  and one of the “100 Most Inspiring People in Life Sciences” by PharmaVOICE magazine. She co-founded the Biomedical Diagnostics master’s degree program at Arizona State University, the only program dedicated exclusively to diagnostics, genetics and genomics. She publishes the widely read Sensitive & Specific: The Diagnostics Newsletter. During the pandemic, she was an advisor to The Rockefeller Foundation on COVID. Mara earned a Master of Business Administration in management from Harvard Business School after receiving a Bachelor of Arts in international relations and Chinese from Tufts University. “As Mara is a healthcare industry thought leader committed to helping biotech companies achieve success, she will be a strong asset to our team and our work at Illumina Ventures,” added Dr. Naclerio. About Illumina Ventures Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina (NASDAQ: ILMN). As an early-stage, value-add investor, Illumina Ventures helps entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare. The firm focuses on investment in life science tools, therapeutics, diagnostics, personal wellness and sustainability. For more information, visit illuminaventures.com. Editors Note:  Mara G. Aspinall is a member of the AZBio Board of Directors . Click the image to learn more Click the image to learn more Click the image to learn more about AZBio Membership Click the image to learn more Click the image to enter the AZBio Career Center Click the image to learn more about the AZBio/AZAdvances Public Information Campaign Patients are why we do what we do. Click the image to listen to their stories.

Illumina Ventures Investments

62 Investments

Illumina Ventures has made 62 investments. Their latest investment was in Broken String Biosciences as part of their Series A on September 9, 2023.

CBI Logo

Illumina Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/18/2023

Series A

Broken String Biosciences

$15M

Yes

2

8/17/2023

Series B

Lightcast Discovery

$49M

Yes

1

7/6/2023

Series A - II

Actym Therapeutics

$11.24M

No

1

6/20/2023

Series A

Subscribe to see more

$99M

Subscribe to see more

10

5/24/2023

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/18/2023

8/17/2023

7/6/2023

6/20/2023

5/24/2023

Round

Series A

Series B

Series A - II

Series A

Series A

Company

Broken String Biosciences

Lightcast Discovery

Actym Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$15M

$49M

$11.24M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

1

1

10

10

Illumina Ventures Portfolio Exits

5 Portfolio Exits

Illumina Ventures has 5 portfolio exits. Their latest portfolio exit was Cernostics on October 19, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/19/2021

Acquired

$99M

3

6/17/2021

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

10/30/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/31/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

5/29/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/19/2021

6/17/2021

10/30/2020

10/31/2018

5/29/2018

Exit

Acquired

Reverse Merger

IPO

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Illumina Ventures Fund History

2 Fund Histories

Illumina Ventures has 2 funds, including Illumina Innovation Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/20/2021

Illumina Innovation Fund II

$325M

3

10/16/2017

Illumina Innovation Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

9/20/2021

10/16/2017

Fund

Illumina Innovation Fund II

Illumina Innovation Fund I

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$325M

$99M

Sources

3

10

Illumina Ventures Partners & Customers

1 Partners and customers

Illumina Ventures has 1 strategic partners and customers. Illumina Ventures recently partnered with AltaReturn on April 4, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

4/24/2017

Vendor

United States

AltaReturn selected by Illumina Ventures - Allvue Systems

About Illumina Ventures : Illumina Ventures is an independently-managed venture fund with A strategic partnership with Illumina Ventures .

1

Date

4/24/2017

Type

Vendor

Business Partner

Country

United States

News Snippet

AltaReturn selected by Illumina Ventures - Allvue Systems

About Illumina Ventures : Illumina Ventures is an independently-managed venture fund with A strategic partnership with Illumina Ventures .

Sources

1

Illumina Ventures Service Providers

1 Service Provider

Illumina Ventures has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Illumina Ventures Team

3 Team Members

Illumina Ventures has 3 team members, including current Chief Information Officer, Omer Ayfer.

Name

Work History

Title

Status

Omer Ayfer

Chief Information Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Omer Ayfer

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Information Officer

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.